Working Market for Patients Living With Advanced Breast Cancer in Portugal: Call for Action
Author(s)
Borges M1, Silva Miguel L2, Oliveira T1, Bulhosa C1, Matos L3, Pinheiro B4, Fidalgo Freitas T5, Cardoso F3
1IQVIA Portugal, Lisbon, Portugal, 2IQVIA Portugal, Salvo, Oeiras, 13, Portugal, 3Champalimaud Clinical Centre, Lisbon, Portugal, 4IQVIA Portugal, Lisboa, Portugal, 5Universidade de Lisboa, Lisboa, PORTUGAL, Portugal
Presentation Documents
OBJECTIVES: This study aims to quantify the productivity costs of premature abandonment of work market of women living with advanced breast cancer (ABC) as well as to evaluate possible labour market policies designed to promote employment
METHODS: The analysis is based on (i) an original cumulative incidence model that allows estimation of the prevalence of working-aged women with ABC in 2019 and on (ii) an observational study that characterises the employment status and working conditions of patients with ABC in Portugal. To determine productivity costs, the human capital approach was adopted.
RESULTS: A total of 2,151 working-aged women were estimated to have ABC in 2019, with productivity costs amounting to 28,676,754€ over the period 2019-2021. Moreover, government transfers (unemployment subsidies and disability pensions) were estimated to be 3,468,866€.
A subsidised part-time employment policy designed to encourage women with ABC to continue working was modelled. The estimated increased cost of this policy is 11,951,048€ over a three-year period, allowing a reduction of 14,338,377€ in productivity costs, leading to a positive balance of 2,431,329€ over the same period.CONCLUSIONS: These results call for changes in labour market laws to enable all patients living with metastatic cancers the right to choose part-time and/or flexible working, without depending on the employer permission as currently stated in the law.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
HPR52
Topic
Health Policy & Regulatory
Topic Subcategory
Public Spending & National Health Expenditures
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology